BioSpace News Archive

BioArctic AB announced that its partner Eisai has published an article about long-term health outcomes of anti-amyloid-beta protofibril[1] antibody lecanemab in people living with mild cognitive impairment due to Alzheimer’s disease and mild AD using a disease simulation model in the peer-reviewed journal Neurology and Therapy.

Mitsubishi Tanabe Pharma America, Inc. announced that its U.S. parent company, Mitsubishi Tanabe Pharma Holdings America, Inc. and their development entity, Mitsubishi Tanabe Pharma Development America, Inc., have merged into MTPA, effective April 1, 2023.

Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, announced the appointment of Craig Collard as Chief Executive Officer.

Scioto Biosciences Inc., (the “Company” or “Scioto Biosciences”) a clinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced the publication of results from a Phase 1b study of their lead product SB-121 in patients with Autistic Spectrum Disorder (ASD).

InnerScope Hearing Technologies Inc., an emerging and disruptive leader in the Over-the-Counter hearing aid space, announced its unaudited financial results for the full year ended December 31, 2022.

BostonGene announced that it will participate and present at the hubXchange’s East Coast Genomics in Precision Oncology 2023, taking place April 5 in Boston, Massachusetts.

Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrating that CampbellCell universal donor stem cells reduce symptoms of schizophrenia in an animal model through stimulation of immune modulation and production of the cytokine brain derived neurotrophic factors (BDNF).

Nymox Pharmaceutical Corporation is pleased to provide a current update on the Company’s ongoing projects.

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2023 on Wednesday, April 26, 2023 at 8:00 a.m. EDT.

Alzamend Neuro, Inc. requests that their press release NewsItemId: 20230403005455 “Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type” be killed.